title: Reply to K.I. Pritchard.
authors.affiliation: Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
authors.forename: N Lynn
authors.initials: NL
authors.lastname: Henry
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
mesh_terms: D000730:Androstadienes / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D042361:Mammary Glands, Human / Q000187:drug effects*; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data*; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen